AR055282A1 - Sal l-tartrato de n-1- adamantil -2-{ 3- [ (2r)-2-({(2r)-2-hidroxi-2-[4- hidroxi-3-(hidroximetil) fenil] etil} amino ) propil] fenil } acetamida - Google Patents

Sal l-tartrato de n-1- adamantil -2-{ 3- [ (2r)-2-({(2r)-2-hidroxi-2-[4- hidroxi-3-(hidroximetil) fenil] etil} amino ) propil] fenil } acetamida

Info

Publication number
AR055282A1
AR055282A1 ARP050104741A ARP050104741A AR055282A1 AR 055282 A1 AR055282 A1 AR 055282A1 AR P050104741 A ARP050104741 A AR P050104741A AR P050104741 A ARP050104741 A AR P050104741A AR 055282 A1 AR055282 A1 AR 055282A1
Authority
AR
Argentina
Prior art keywords
phenyl
hydroxy
acetamide
amino
salt
Prior art date
Application number
ARP050104741A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR055282A1 publication Critical patent/AR055282A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente se refiere a la sal L-tartrato de N-1-adamantil-2-{3-[(2R)-2-({(2R)-2-hidroxi-2-[4-hidroxi-3-(hidroximetil)fenil]etil}amino)propil]fenil}acetamida y a su uso como medicamento. Reivindicacion 2: Un compuesto segun la reivindicacion 1 que tiene un patron de difraccion por rayos X caracterizado por los siguientes picos principales del patron de difraccion por rayos X expresados en términos de ángulo 2-theta (longitud de onda = 1,54178 Angstroms) Angulo 2-theta(+/-0,1 grados),14,9, 16,7, 18,3, 19,1, 20,6, 20,9.
ARP050104741A 2004-11-12 2005-11-11 Sal l-tartrato de n-1- adamantil -2-{ 3- [ (2r)-2-({(2r)-2-hidroxi-2-[4- hidroxi-3-(hidroximetil) fenil] etil} amino ) propil] fenil } acetamida AR055282A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0425057A GB0425057D0 (en) 2004-11-12 2004-11-12 L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide

Publications (1)

Publication Number Publication Date
AR055282A1 true AR055282A1 (es) 2007-08-15

Family

ID=33523659

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104741A AR055282A1 (es) 2004-11-12 2005-11-11 Sal l-tartrato de n-1- adamantil -2-{ 3- [ (2r)-2-({(2r)-2-hidroxi-2-[4- hidroxi-3-(hidroximetil) fenil] etil} amino ) propil] fenil } acetamida

Country Status (8)

Country Link
AR (1) AR055282A1 (es)
GB (1) GB0425057D0 (es)
GT (1) GT200500328A (es)
NL (1) NL1030405C2 (es)
PE (1) PE20061131A1 (es)
TW (1) TW200630324A (es)
UY (1) UY29207A1 (es)
WO (1) WO2006051375A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
HRP20221196T1 (hr) 2017-10-05 2022-12-09 Fulcrum Therapeutics, Inc. Inhibitori p38 kinaze smanjuju ekspresiju dux4 i nizvodnih gena u cilju liječenja fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003222841A1 (en) * 2002-04-25 2003-11-10 Glaxo Group Limited Phenethanolamine derivatives
EP1460064A1 (en) * 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
EP1577291A1 (en) * 2004-03-17 2005-09-21 Pfizer Limited Phenylethanolamine derivatives as beta-2 agonists

Also Published As

Publication number Publication date
UY29207A1 (es) 2006-06-30
GT200500328A (es) 2006-06-02
NL1030405C2 (nl) 2006-12-12
WO2006051375A1 (en) 2006-05-18
TW200630324A (en) 2006-09-01
PE20061131A1 (es) 2006-10-20
GB0425057D0 (en) 2004-12-15
NL1030405A1 (nl) 2006-05-15

Similar Documents

Publication Publication Date Title
AR055282A1 (es) Sal l-tartrato de n-1- adamantil -2-{ 3- [ (2r)-2-({(2r)-2-hidroxi-2-[4- hidroxi-3-(hidroximetil) fenil] etil} amino ) propil] fenil } acetamida
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
EP2690348A3 (en) Projector type headlight
AR059518A1 (es) Metodos para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios
DOP2010000271A (es) Compuestos plaguicidas de arilo de anillo condensado
ES2496092T3 (es) El uso de amisulprida para tratar náuseas y vómitos posoperatorios
PE20120083A1 (es) Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a
CL2008002319A1 (es) Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
EA200900098A1 (ru) Пептидные соединения для лечения расстройств, связанных с повышенной возбудимостью, и болезней, связанных с дисфункцией ионных каналов
NI200900032A (es) Compuestos de pirido (2, 3-d) pirimidinonay su uso como inhibidores de pi3
PE20142454A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
SV2011003894A (es) Nuevos compuestos halosustituidos
PE20142329A1 (es) Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]decan-2-ona
ES2544954T3 (es) Péptidos multiméricos ramificados para diagnóstico y terapia de tumores
EA200702039A1 (ru) 7-аминоалкилиденилгетероциклические хинолоны и нафтиридоны
BRPI0913291A2 (pt) composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
UY29723A1 (es) Uso de arilanilidas para tratamiento de semillas
MX2010003653A (es) Marcador vial reflectante.
CL2011000100A1 (es) Uso de un inhibidor de desacetilasa de histona para el tratamiento de la enfermedad de hodgkin.
BRPI0507916A (pt) moduladores de oxidecahidronaftaleno de hm74
EA201390635A1 (ru) Эффективные реакции пептидного сочетания и их применение для получения и выделения тринатриевой соли циклопента[g]хиназолина
BR112022001793A2 (pt) Método para tratar a doença de alzheimer inibindo-se a absorção de aminoácidos por células t
CL2008000150A1 (es) Formas cristalinas de compuestos derivados de n-(2-amino fenil)-4-pirazol-1-il metil benzamida; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico que comprende a dichos compuestos; y su uso para tratar cancer, psoriasis, ar
GT200600094A (es) Reduccion de la digeribilidad del fosforo

Legal Events

Date Code Title Description
FB Suspension of granting procedure